NCT03380026View on ClinicalTrials.gov

Mechlorethamine Induced Contact Dermatitis Avoidance Study

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 13, 2017

Primary Completion Date

August 3, 2020

Study Completion Date

December 13, 2020

Conditions
Cutaneous T-cell LymphomaCutaneous T-cell Lymphoma Stage IMycosis FungoidesFolliculotropic Mycosis FungoidesGranulomatous Slack SkinSyringotropic Mycosis FungoidesMycosis Fungoides VariantTransformed Mycosis Fungoides
Interventions
DRUG

Triamcinolone

Apply up to three times daily on select lesions.

DRUG

Valchlor 0.016 % Topical Gel

Apply valchlor nightly on select lesions.

Trial Locations (1)

14450

Rochester Skin Lymphoma Medical Group, PLLC, Fairport

All Listed Sponsors
collaborator

Rochester General Hospital

OTHER

lead

Rochester Skin Lymphoma Medical Group, PLLC

OTHER

NCT03380026 - Mechlorethamine Induced Contact Dermatitis Avoidance Study | Biotech Hunter | Biotech Hunter